Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 1979654, 9 pages
http://dx.doi.org/10.1155/2016/1979654
Review Article

Inositol Treatment and ART Outcomes in Women with PCOS

1Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY, USA
2Division of Reproductive Endocrinology & Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA

Received 19 June 2016; Accepted 30 August 2016

Academic Editor: Nikos Prapas

Copyright © 2016 Deepika Garg and Reshef Tal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. S. Knochenhauer, T. J. Key, M. Kahsar-Miller, W. Waggoner, L. R. Boots, and R. Azziz, “Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: A Prospective Study,” The Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 9, pp. 3078–3082, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. B. C. J. M. Fauser, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 19–25, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Tal, D. B. Seifer, and A. Arici, “The emerging role of angiogenic factor dysregulation in the pathogenesis of polycystic ovarian syndrome,” Seminars in Reproductive Medicine, vol. 33, no. 3, pp. 195–207, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Dunaif, K. R. Segal, W. Futterweit, and A. Dobrjansky, “Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome,” Diabetes, vol. 38, no. 9, pp. 1165–1174, 1989. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Toprak, A. Yönem, B. Çakir et al., “Insulin resistance in nonobese patients with polycystic ovary syndrome,” Hormone Research, vol. 55, no. 2, pp. 65–70, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. J. K. Zawadski and A. Dunaif, “Diagnostic criteria for polycystic ovary syndrome: towards a rational approach,” in Polycystic Ovary Syndrome, A. Dunaif, J. R. Givens, F. P. Haseltine, and G. R. Merriam, Eds., pp. 377–384, Blackwell Scientific, Boston, Mass, USA, 1992. View at Google Scholar
  7. M. Ciampelli, A. M. Fulghesu, F. Cucinelli et al., “Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome,” Metabolism: Clinical and Experimental, vol. 48, no. 2, pp. 167–172, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. A. D. Genazzani, C. Battaglia, B. Malavasi, C. Strucchi, F. Tortolani, and O. Gamba, “Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 114–119, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. V. De Leo, A. La Marca, and F. Petraglia, “Insulin-lowering agents in the management of polycystic ovary syndrome,” Endocrine Reviews, vol. 24, no. 5, pp. 633–667, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. D. Genazzani, C. Lanzoni, F. Ricchieri, and V. M. Jasonni, “Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 24, no. 3, pp. 139–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Papaleo, V. Unfer, J.-P. Baillargeon, F. Fusi, F. Occhi, and L. De Santis, “Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial,” Fertility and Sterility, vol. 91, no. 5, pp. 1750–1754, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Gerli, E. Papaleo, A. Ferrari, and G. C. di Renzo, “Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS,” European Review for Medical and Pharmacological Sciences, vol. 11, no. 5, pp. 347–354, 2007. View at Google Scholar · View at Scopus
  13. I. Vucenik and A. M. Shamsuddin, “Protection against cancer by dietary IP6 and inositol,” Nutrition and Cancer, vol. 55, no. 2, pp. 109–125, 2006. View at Publisher · View at Google Scholar
  14. R. S. Clements Jr. and B. Darnell, “Myo-inositol content of common foods: development of a high-myo-inositol diet,” The American Journal of Clinical Nutrition, vol. 33, no. 9, pp. 1954–1967, 1980. View at Google Scholar · View at Scopus
  15. J. E. F. Reynolds, Martindale: The Extra Pharmacopoeia 30, Rittenhouse Book Distributors, King of Prussia, Pa, USA, 1993.
  16. J. E. Nestler, D. J. Jakubowicz, P. Reamer, R. D. Gunn, and G. Allan, “Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome,” The New England Journal of Medicine, vol. 340, no. 17, pp. 1314–1320, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Minozzi, G. D'Andrea, and V. Unfer, “Treatment of hirsutism with myo-inositol: A Prospective Clinical Study,” Reproductive BioMedicine Online, vol. 17, no. 4, pp. 579–582, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Papaleo, V. Unfer, J. P. Baillargeon, and T. T. Chiu, “Contribution of myo-inositol to reproduction,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 147, no. 2, pp. 120–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. G. E. Gillaspy, J. S. Keddie, K. Oda, and W. Gruissem, “Plant inositol monophosphatase is a lithium-sensitive enzyme encoded by a multigene family,” Plant Cell, vol. 7, no. 12, pp. 2175–2185, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. T.-H. Sun, D. B. Heimark, T. Nguygen, J. L. Nadler, and J. Larner, “Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls,” Biochemical and Biophysical Research Communications, vol. 293, no. 3, pp. 1092–1098, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. M. Zacchè, L. Caputo, S. Filippis, G. Zacchè, M. Dindelli, and A. Ferrari, “Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 25, no. 8, pp. 508–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Costantino, G. Minozzi, F. Minozzi, and C. Guaraldi, “Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial,” European Review for Medical and Pharmacological Sciences, vol. 13, no. 2, pp. 105–110, 2009. View at Google Scholar · View at Scopus
  23. E. Papaleo, V. Unfer, J.-P. Baillargeon et al., “Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction,” Gynecological Endocrinology, vol. 23, no. 12, pp. 700–703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. P. T. Goud, A. P. Goud, P. Van Oostveldt, and M. Dhont, “Presence and dynamic redistribution of type I inositol 1,4,5-trisphosphate receptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions,” Molecular Human Reproduction, vol. 5, no. 5, pp. 441–451, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Iuorno, D. J. Jakubowicz, J.-P. Baillargeon et al., “Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome,” Endocrine Practice, vol. 8, no. 6, pp. 417–423, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Chattopadhayay, A. Ganesh, J. Samanta, S. K. Jana, B. N. Chakravarty, and K. Chaudhury, “Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome,” Gynecologic and Obstetric Investigation, vol. 69, no. 3, pp. 197–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, T. Apridonidze, N. He, and J. E. Nestler, “Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 1, pp. 242–249, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Colazingari, M. Treglia, R. Najjar, and A. Bevilacqua, “The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial,” Archives of Gynecology and Obstetrics, vol. 288, no. 6, pp. 1405–1411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Bevilacqua and M. Bizzarri, “Physiological role and clinical utility of inositols in polycystic ovary syndrome,” Best Practice & Research. Clinical Obstetrics & Gynaecology, 2016. View at Publisher · View at Google Scholar
  30. M. J. Coady, B. Wallendorff, D. G. Gagnon, and J.-Y. Lapointe, “Identification of a novel Na+/myo-inositol cotransporter,” The Journal of Biological Chemistry, vol. 277, no. 38, pp. 35219–35224, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. R. E. Ostlund Jr., R. Seemayer, S. Gupta, R. Kimmel, E. L. Ostlund, and W. R. Sherman, “A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells: identification with D-chiro-[3-3H]inositol,” The Journal of Biological Chemistry, vol. 271, no. 17, pp. 10073–10078, 1996. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Pesty, B. Lefevre, J. Kubiak, G. Geraud, J. Tesarik, and B. Maro, “Mouse oocyte maturation is affected by lithium via the polyphosphoinositide metabolism and the microtubule network,” Molecular Reproduction and Development, vol. 38, no. 2, pp. 187–199, 1994. View at Publisher · View at Google Scholar · View at Scopus
  33. S. DeLisle, O. Blondel, F. J. Longo, W. E. Schnabel, G. I. Bell, and M. J. Welsh, “Expression of inositol 1,4,5-trisphosphate receptors changes the Ca2+ signal of Xenopus oocytes,” The American Journal of Physiology, vol. 270, no. 4, part 1, pp. C1255–C1261, 1996. View at Google Scholar
  34. M. Herbert, A. P. Murdoch, and J. I. Gillespie, “The thiol reagent, thimerosal induces intracellular calcium oscillations in mature human oocytes,” Human Reproduction, vol. 10, no. 8, pp. 2183–2186, 1995. View at Google Scholar · View at Scopus
  35. M. Sousa, A. Barros, and J. Tesarik, “Developmental changes in calcium dynamics, protein kinase C distribution and endoplasmic reticulum organization in human preimplantation embryos,” Molecular Human Reproduction, vol. 2, no. 12, pp. 967–977, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. T. T. Y. Chiu and P. P. L. Tam, “A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum,” Journal of Assisted Reproduction and Genetics, vol. 9, no. 6, pp. 524–530, 1992. View at Publisher · View at Google Scholar · View at Scopus
  37. T. T. Y. Chiu, M. S. Rogers, C. Briton-Jones, and C. Haines, “Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes,” Human Reproduction, vol. 18, no. 2, pp. 408–416, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Colazingari, M. T. Fiorenza, G. Carlomagno, R. Najjar, and A. Bevilacqua, “Improvement of mouse embryo quality by myo-inositol supplementation of IVF media,” Journal of Assisted Reproduction and Genetics, vol. 31, no. 4, pp. 463–469, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Caprio, M. D. D'Eufemia, C. Trotta et al., “Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial,” Journal of Ovarian Research, vol. 8, no. 1, article 37, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Minozzi, D. Costantino, C. Guaraldi, and V. Unfer, “The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome,” Gynecological Endocrinology, vol. 27, no. 11, pp. 920–924, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Ciotta, M. Stracquadanio, I. Pagano, A. Carbonaro, M. Palumbo, and F. Gulino, “Effects of Myo-Inositol supplementation on oocyte's quality in PCOS patients: a double blind trial,” European Review for Medical and Pharmacological Sciences, vol. 15, no. 5, pp. 509–514, 2011. View at Google Scholar · View at Scopus
  42. G. A. Burghen, J. R. Givens, and A. E. Kitabchi, “Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease,” Journal of Clinical Endocrinology and Metabolism, vol. 50, no. 1, pp. 113–116, 1980. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Dunaif, “Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis,” Endocrine Reviews, vol. 18, no. 6, pp. 774–800, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Dunaif, “Insulin resistance in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 86, no. 1, pp. S13–S14, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. M. J. Iuorno and J. E. Nestler, “Insulin-lowering drugs in polycystic ovary syndrome,” Obstetrics and Gynecology Clinics of North America, vol. 28, no. 1, pp. 153–164, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. L. C. Huang, M. C. Fonteles, D. B. Houston, C. Zhang, and J. Larner, “Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo,” Endocrinology, vol. 132, no. 2, pp. 652–657, 1993. View at Google Scholar · View at Scopus
  47. H. K. Ortmeyer, “Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys,” Obesity Research, vol. 4, no. 6, pp. 569–575, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. J.-P. Baillargeon, E. Diamanti-Kandarakis, R. E. Ostlund Jr., T. Apridonidze, M. J. Iuorno, and J. E. Nestler, “Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome,” Diabetes Care, vol. 29, no. 2, pp. 300–305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. J.-P. Baillargeon, J. E. Nestler, R. E. Ostlund, T. Apridonidze, and E. Diamanti-Kandarakis, “Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism,” Human Reproduction, vol. 23, no. 6, pp. 1439–1446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-P. Baillargeon, M. J. Iuorno, T. Apridonidze, and J. E. Nestler, “Uncoupling between insulin and release of a d-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome,” Metabolic Syndrome and Related Disorders, vol. 8, no. 2, pp. 127–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. J. E. Nestler, “Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 9, no. 2–4, pp. 197–204, 1998. View at Google Scholar · View at Scopus
  52. J. E. Nestler, D. J. Jakubowicz, and M. J. Iuorno, “Role of inositolphophoglycan mediators of insulin action in the polycystic ovary syndrome,” Journal of Pediatric Endocrinology & Metabolism, vol. 13, no. 5, pp. 1295–1298, 2000. View at Google Scholar · View at Scopus
  53. K. I. Cheang, J.-P. Baillargeon, P. A. Essah et al., “Insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome,” Metabolism: Clinical and Experimental, vol. 57, no. 10, pp. 1390–1397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Isabella and E. Raffone, “Does ovary need D-chiro-inositol?” Journal of Ovarian Research, vol. 5, article 14, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Pak, L. C. Huang, K. J. Lilley, and J. Larner, “In Vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues,” The Journal of Biological Chemistry, vol. 267, no. 24, pp. 16904–16910, 1992. View at Google Scholar · View at Scopus
  56. J. Larner, “D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance,” International Journal of Experimental Diabetes Research, vol. 3, no. 1, pp. 47–60, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Larner and J. W. Craig, “Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance,” Diabetes Care, vol. 19, no. 1, pp. 76–78, 1996. View at Publisher · View at Google Scholar · View at Scopus
  58. I. Asplin, G. Galasko, and J. Larner, “chiro-Inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 13, pp. 5924–5928, 1993. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Rice, N. Christoforidis, C. Gadd et al., “Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries,” Human Reproduction, vol. 20, no. 2, pp. 373–381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Harwood, P. Vuguin, and J. DiMartino-Nardi, “Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth,” Hormone Research, vol. 68, no. 5, pp. 209–217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Heimark, J. McAllister, and J. Larner, “Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls,” Endocrine Journal, vol. 61, no. 2, pp. 111–117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Dinicola, T. T. Y. Chiu, V. Unfer, G. Carlomagno, and M. Bizzarri, “The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome,” Journal of Clinical Pharmacology, vol. 54, no. 10, pp. 1079–1092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. Z. Kamenov, G. Kolarov, A. Gateva, G. Carlomagno, and A. D. Genazzani, “Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance,” Gynecological Endocrinology, vol. 31, no. 2, pp. 131–135, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. P. G. Artini, O. M. Di Berardino, F. Papini et al., “Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study,” Gynecological Endocrinology, vol. 29, no. 4, pp. 375–379, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Minozzi, M. Nordio, and R. Pajalich, “The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 4, pp. 537–540, 2013. View at Google Scholar · View at Scopus
  66. M. Nordio and E. Proietti, “The Combined therapy with myo-inositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 5, pp. 575–581, 2012. View at Google Scholar · View at Scopus
  67. B. K. Arya, A. U. Haq, and K. Chaudhury, “Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism,” Medical Hypotheses, vol. 78, no. 4, pp. 475–478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Ferrari, F. Facchinetti, A. E. Ontiveros et al., “The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity,” American Journal of Obstetrics and Gynecology, 2016. View at Publisher · View at Google Scholar
  69. M. Bizzarri and G. Carlomagno, “Inositol: history of an effective therapy for polycystic ovary syndrome,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 13, pp. 1896–1903, 2014. View at Google Scholar · View at Scopus
  70. V. Unfer, G. Carlomagno, P. Rizzo, E. Raffone, and S. Roseff, “Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial,” European Review for Medical and Pharmacological Sciences, vol. 15, no. 4, pp. 452–457, 2011. View at Google Scholar · View at Scopus
  71. G. Carlomagno, V. Unfer, and S. Roseff, “The D-chiro-inositol paradox in the ovary,” Fertility and Sterility, vol. 95, no. 8, pp. 2515–2516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Pacchiarotti, G. Carlomagno, G. Antonini, and A. Pacchiarotti, “Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome,” Gynecological Endocrinology, vol. 32, no. 1, pp. 69–73, 2016. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Rago, I. Marcucci, G. Leto et al., “Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study,” Journal of Biological Regulators and Homeostatic Agents, vol. 29, no. 4, pp. 913–923, 2015. View at Google Scholar